Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 430

1.

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.

Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.

Hepatology. 2012 Aug;56(2):567-75. doi: 10.1002/hep.25865. Epub 2012 Jun 29.

PMID:
22619063
2.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Epub 2012 Sep 11. Review.

PMID:
22975763
3.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747
4.

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.

Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP.

J Hepatol. 2014 Apr;60(4):748-56. doi: 10.1016/j.jhep.2013.12.013. Epub 2013 Dec 19.

PMID:
24362076
5.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
6.

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):81-87.e4; quiz e5. doi: 10.1016/j.cgh.2012.10.006. Epub 2012 Oct 10.

PMID:
23064222
7.

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.

Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH.

J Hepatol. 2013 Mar;58(3):479-87. doi: 10.1016/j.jhep.2012.11.020. Epub 2012 Nov 23.

PMID:
23183529
8.

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group.

J Infect Dis. 2012 Sep 15;206(6):961-8. Epub 2012 Jul 17.

10.

Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.

Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ.

J Clin Gastroenterol. 2014 May-Jun;48(5):435-43. doi: 10.1097/MCG.0000000000000000.

PMID:
24177376
11.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-18.e1-5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
12.

Boceprevir for previously treated chronic HCV genotype 1 infection.

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1207-17. doi: 10.1056/NEJMoa1009482.

13.

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.

Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM.

Hepatology. 2012 Aug;56(2):464-73. doi: 10.1002/hep.25661. Epub 2012 Jun 11.

PMID:
22334369
14.

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Garnock-Jones KP.

Drugs. 2012 Dec 24;72(18):2431-56. doi: 10.2165/11209560-000000000-00000. Review.

PMID:
23231027
15.

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.

Foote BS, Spooner LM, Belliveau PP.

Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Review.

PMID:
21828346
16.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators.

N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.

17.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
18.

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD008516. doi: 10.1002/14651858.CD008516.pub2. Review.

PMID:
22972122
19.

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.

Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Sugiura N, Tawada A, Wu S, Tanaka T, Nakamoto S, Mikata R, Tada M, Chiba T, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O.

J Viral Hepat. 2011 Jul;18(7):e292-7. doi: 10.1111/j.1365-2893.2010.01409.x. Epub 2010 Dec 3.

PMID:
21129130
20.

[Retreatment options for patients with chronic hepatitis C].

Hrstić I, Ostojić R, Vucelić B.

Acta Med Croatica. 2009 Dec;63(5):417-22. Croatian.

PMID:
20198901
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk